… lesion) of 1.5 g/5 mL meglumine antimoniate (Glucantime®) were recommended (all injections
were performed by the same dermatologist). Each lesion … for each lesion was 0.2–0.8 mL. …

… Cutaneous leishmaniasis is a serious public health problem in the developing world. The …
use of meglumine antimoniate alone and in combination for the initial treatment of cutaneous …

… , meglumine antimoniate, and with each other in 120 Ecuadorian patients with ulcerated
lesions… Group 3 (n=40) received 20 mg/kg/day of IM meglumine antimoniate (MA) for 10 days as …

SciELO - Brasil - Intralesional meglumine antimoniate for the treatment of localised cutaneous
leishmaniasis: a retrospective review of a Brazilian referral centre Intralesional meglumine …

… of Sb) into each lesion along with intramuscular injection of meglumine … meglumine
antimoniate (MA) alone and in combination with intralesional meglumine antimoniate in cutaneous …

… We highlight that, due to the characteristics of their cutaneous lesions, five of these six
patients presented contraindications to IL-MA according to current recommendations (Brasil MS - …

… meglumine antimoniate for 25 to 116 days without rest intervals, and 94 (67.6%) intermittent
treatment with 2 to 5 series of meglumine antimoniate. … shown that cutaneous lesions which …

SciELO - Brasil - Meglumine antimoniate intralesional infiltration for localised cutaneous
leishmaniasis: a single arm, open label, phase II clinical trial Meglumine antimoniate …

… related to the site of the skin lesion, observed in 84.9% of the participants. Pruritus, edema
and pain in the skin lesion site were the most reported symptoms. All the AEs were graded as …

… the incidence of adverse symptoms. The levels of antimony in plasma and skin samples were
… The mean antimony level in their skin at the end of the treatment was 9.24 μg/g. The main …